Covid-19 | Page 23 of 100 | Links Medicus Content Curation & Alerts in Medicine

Covid-19: What do we know about omicron sublineages?

13 Feb, 2022 | 22:42h | UTC

Covid-19: What do we know about omicron sublineages? – The BMJ

We regret to inform you that we are now discussing subvariants – Vox

Sudden rise of more transmissible form of Omicron catches scientists by surprise.

Omicron’s sister variant spreads faster. So why did the one we call Omicron hit first?

[Preprint] Study suggests SARS-CoV-2 Omicron subvariants BA.2 is even more transmissible than the original variant.

BA.2 is like Omicron’s sister. Here’s what we know about it so far – The Conversation

Commentary on Twitter

In November 2021 WHO designated omicron a variant of concern. With its sublineage BA.2 now widespread, @emahase_ looks at what science has found out about the variant and its three (so far) variations https://t.co/HjBZSwCATW

— The BMJ (@bmj_latest) February 13, 2022

Conflicting reports raise questions about whether any monoclonals work against Omicron’s sister variant.

13 Feb, 2022 | 22:49h | UTC

Conflicting reports raise questions about whether any monoclonals work against Omicron’s sister variant – STAT

FDA halts use of antibody drugs that don’t work vs. Omicron.

Lab study shows new antiviral pills maintain efficacy against Omicron, but antibody drugs are substantially less effective.

ERS statement on Long COVID-19 follow-up.

13 Feb, 2022 | 22:48h | UTC

European Respiratory Society Statement on Long COVID-19 Follow-Up – European Respiratory Review

First research definition for ‘Long COVID’ in kids and young people formally agreed.

13 Feb, 2022 | 22:45h | UTC

News Release: First research definition for ‘Long COVID’ in kids and young people formally agreed – BMJ

Original Article (preprint): Long COVID (Post-COVID-19 condition) in Children: a modified Delphi Process – Archives of Disease in Childhood

Commentaries:

Expert reaction to Delphi consensus study on a long-COVID definition in children – Science Media Centre

Long covid: “Holistic” approach is best, given range of symptoms, say researchers – The BMJ

Cohort Study: Physical and mental health 3 months after SARS-CoV-2 infection (long COVID) among adolescents in England.

A nationwide cohort study in Denmark showed Long Covid in children is rare and mainly of short duration.

E ditorial | Long covid in children and adolescents – “Risk appears low, but many questions remain”.

M-A: Persistent symptoms following SARS-CoV-2 infection among children and young people – “Higher study quality was associated with lower prevalence of all symptoms, except loss of smell and cognitive symptoms”.

Review: Long COVID symptoms in children rarely persist beyond three months.

Cohort study: long term follow-up showed most patients with post–COVID-19 Multisystem Inflammatory Syndrome in Children had good outcomes with no significant medium- or long-term sequelae.

Do kids get long COVID? And how often? A pediatrician looks at the data – Children also get Long Covid, but much less often than adults.

Illness duration and symptom profile in symptomatic school-aged children tested for SARS-CoV-2 – “Only 25 (1.8%) of 1379 children experienced symptoms for at least 56 days.”

Long-term Symptoms After SARS-CoV-2 Infection in Children and Adolescents – “This study found a low prevalence of symptoms compatible with long COVID in a randomly selected cohort of children assessed 6 months after serologic testing”.

Study shows low incidence of post-acute COVID-19 symptoms (“Long Covid”) in children after mild disease

Babies born during pandemic’s first year score slightly lower on a developmental screening test.

11 Feb, 2022 | 08:46h | UTC

News Release: Babies born during pandemic’s first year score slightly lower on a developmental screening test – Columbia University Irving Medical Center

Original Study: Association of Birth During the COVID-19 Pandemic With Neurodevelopmental Status at 6 Months in Infants With and Without In Utero Exposure to Maternal SARS-CoV-2 Infection – JAMA Pediatrics

Editorial: Understanding the Effects of the Pandemic on Infant Development—The Preterm Problem

Commentaries:

Covid-19: Babies born during the pandemic show slight development delays – The BMJ

Pandemic birth tied to poor development – CIDRAP

Audio Interview: Covid-19 as an endemic disease.

11 Feb, 2022 | 08:47h | UTC

Audio Interview: Covid-19 as an Endemic Disease – New England Journal of Medicine

Recovering from a pandemic: pulmonary fibrosis after SARS-CoV-2 infection.

11 Feb, 2022 | 08:44h | UTC

Recovering from a pandemic: pulmonary fibrosis after SARS-CoV-2 infection – European Respiratory Review

Sweden ends COVID-19 testing as pandemic restrictions lifted – “only health care and elderly care workers and the most vulnerable will be entitled to free PCR testing if they are symptomatic, while the rest of the population will simply be asked to stay home if they show symptoms that could be COVID-19”.

10 Feb, 2022 | 10:07h | UTC

Sweden ends COVID-19 testing as pandemic restrictions lifted – Associated Press

How Denmark Decided COVID Isn’t a Critical Threat to Society – “The country became the first in the EU to lift all COVID restrictions despite leading the world in per capita infections”.

Covid: Europe set for ‘long period of tranquillity’ in pandemic, says WHO.

As Denmark scraps COVID restrictions, WHO urges caution.

Despite the ongoing spread of Omicron, some European countries have decided to lift Covid-19 restrictions.

A population-based study in Qatar showed previous infection provided robust protection against reinfection with the alpha, beta, and delta variants of SARS-CoV-2 (approximately 90%). However, protection against reinfection with the omicron variant was lower (around 60%).

10 Feb, 2022 | 10:04h | UTC

Protection against the Omicron Variant from Previous SARS-CoV-2 Infection – New England Journal of Medicine

Commentary on Twitter

Using a national database in Qatar, investigators found that previous #SARSCoV2 infection provided protection against reinfection that ranged from 85% to 92% for alpha, beta, and delta strains and was approx 60% protective against omicron. #COVID19 https://t.co/SGODYCmkP3 pic.twitter.com/OkgjCbyZBj

— NEJM (@NEJM) February 9, 2022

RCT: Final analysis of efficacy and safety of single-dose J&J vaccine.

10 Feb, 2022 | 10:03h | UTC

Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S – New England Journal of Medicine

Commentary on Twitter

A single injection of the Ad26.COV2.S Covid-19 vaccine showed 56.3% vaccine efficacy beginning 14 days after injection and 52.9% efficacy more than 28 days after injection against moderate to severe–critical #COVID19. #IDTwitter https://t.co/0VhaEUtmwq pic.twitter.com/04QqSyYwNI

— NEJM (@NEJM) February 9, 2022

Vaccine effectiveness of heterologous CoronaVac plus Pfizer in Brazil.

10 Feb, 2022 | 10:01h | UTC

Vaccine effectiveness of heterologous CoronaVac plus BNT162b2 in Brazil – Nature Medicine

Commentary on Twitter

An analysis of data from Brazil in @NatureMedicine shows that vaccine effectiveness against SARS-CoV-2 infection and severe COVID-19 outcomes declines after two doses of CoronaVac but increases after a booster dose of the Pfizer-BioNTech vaccine. https://t.co/UCgy6cJFIP pic.twitter.com/pXvkxZHXvv

— Nature Portfolio (@NaturePortfolio) February 9, 2022

IDSA Updated Covid-19 Guideline now supports the use of convalescent plasma in ambulatory patients with mild to moderate COVID-19 at high risk for progression to severe disease.

9 Feb, 2022 | 10:15h | UTC

IDSA Guidelines on the Treatment and Management of Patients with COVID-19 – Infectious Diseases Society of America

Commentary on Twitter

Update Alert: Revised recommendation on the use of #convalescentplasma in ambulatory patients w/ COVID-19 at high risk of progression to severe disease w/ no other treatment options.

?: https://t.co/YRCxtdilXT #COVID19Guidelines @JGPharmD @adarsh_bhimraj @RMKGandhi @ShohamTxID pic.twitter.com/KpXnywH362

— IDSA (@IDSAInfo) February 8, 2022

WHO: Two years into COVID pandemic, most countries still face significant health service disruptions.

9 Feb, 2022 | 10:13h | UTC

Two Years into COVID Pandemic, Most Countries Still Face Significant Health Service Disruptions – Health Policy Watch

Original Report: Third round of the global pulse survey on continuity of essential health services during the COVID-19 pandemic – World Health Organization

Cohort Study: Physical and mental health 3 months after SARS-CoV-2 infection (long COVID) among adolescents in England.

9 Feb, 2022 | 10:12h | UTC

Physical and mental health 3 months after SARS-CoV-2 infection (long COVID) among adolescents in England (CLoCk): a national matched cohort study – The Lancet Child & Adolescent Health

Editorial: Assessing the impact of the pandemic in children and adolescents: SARS-CoV-2 infection and beyond – The Lancet Child & Adolescent Health

Commentary: Long COVID and kids: more research is urgently needed – Nature

A nationwide cohort study in Denmark showed Long Covid in children is rare and mainly of short duration.

E ditorial | Long covid in children and adolescents – “Risk appears low, but many questions remain”.

Review: Long COVID symptoms in children rarely persist beyond three months.

Cohort study: long term follow-up showed most patients with post–COVID-19 Multisystem Inflammatory Syndrome in Children had good outcomes with no significant medium- or long-term sequelae.

Do kids get long COVID? And how often? A pediatrician looks at the data – Children also get Long Covid, but much less often than adults.

Illness duration and symptom profile in symptomatic school-aged children tested for SARS-CoV-2 – “Only 25 (1.8%) of 1379 children experienced symptoms for at least 56 days.”

Study shows low incidence of post-acute COVID-19 symptoms (“Long Covid”) in children after mild disease

Commentary on Twitter (thread – click for more)

NEW RESEARCH: free! Two studies on adolescent #LongCovid. Both found high symptom burden in COVID positive and negative participants; very heterogenous symptom profile. Pandemic has had profound impact on all adolescents. https://t.co/YzU3ogXZrw pic.twitter.com/ina0DgPxBf

— The Lancet Child & Adolescent Health (@LancetChildAdol) February 8, 2022

Though rare, Moderna Covid vaccine recipients have higher risk of heart inflammation than Pfizer.

9 Feb, 2022 | 10:06h | UTC

Though rare, Moderna Covid vaccine recipients have higher risk of heart inflammation than Pfizer – CNBC

[Preprint] Risk of myocarditis following sequential COVID-19 vaccinations by age and sex.

Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination vs. SARS-CoV-2 infection.

[Preprint] Post-marketing active surveillance of myocarditis and pericarditis following vaccination with COVID-19 mRNA vaccines in persons aged 12-39 years in Italy.

9 Feb, 2022 | 10:08h | UTC

Post-marketing active surveillance of myocarditis and pericarditis following vaccination with COVID-19 mRNA vaccines in persons aged 12-39 years in Italy: a multi-database, self-controlled case series study -medRxiv

Myocarditis after BNT162b2 vaccination in Israeli adolescents.

Myocarditis cases reported after mRNA-Based COVID-19 vaccination in the US from December 2020 to August 2021.

A case-control study showed an increased risk of myocarditis after COVID-19 vaccination with a messenger RNA vaccine compared to an inactivated virus vaccine.

[Preprint] Risk of myocarditis following sequential COVID-19 vaccinations by age and sex.

Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination vs. SARS-CoV-2 infection.

Case series with 139 adolescents and young adults with suspected myocarditis following mRNA vaccination showed most cases had a mild clinical course and rapid resolution of symptoms.

Heart-inflammation risk from Pfizer COVID vaccine is very low.

Large cohort study with over 2.5 million individuals showed the incidence of myocarditis after the Pfizer vaccine was 2.13 cases per 100,000 persons.

Study with over 5.1 million vaccinated individuals showed the incidence of myocarditis after the receipt of the Pfizer vaccine was low and more common after the second dose in young male recipients.

Large Observational study shows Pfizer Covid vaccine is mostly safe but is associated with increased risk of myocarditis, adenopathy, appendicitis, and herpes zoster.

Commentary on Twitter

The incidence of mRNA vaccine myocarditis or pericarditis in Italy in ~3 million vaccinees age 12-39. Excess cases per 100,000; orange is 2nd dose, blue 1st dose. https://t.co/xvdV4qSdHw
Pfizer:~1/100,000 age 12-39, all 2nd dose
Moderna,: >5/100,000, age 12-39, and some 1st dose pic.twitter.com/Y1jfGrU53v

— Eric Topol (@EricTopol) February 9, 2022